We believe it will be critical for BSX to carefully manage its interaction with the FDA.

We believe it will be critical for BSX to carefully manage its interaction with the FDA,

The device replacements will cause companies to forgo revenue producing replacement units in future years.

Overall, we found results in the quarter to be generally weak, but believe the strong market reaction was justified given the anticipated completion of the Guidant vascular acquisition.

Boston Scientific still has much 'wood to chop' regarding the recovery of the company's cardiac rhythm management business...That said, we believe earnings power for businesses remain substantial.

Results were dramatically lower than consensus estimates in both cases and reflect the challenges the company faces in rebuilding its CRM [cardiac rhythm management] business.